Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-10-20

Clinical Trial Update: Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial investigating tocilizumab augmentation in treatment-refractory major depressive disorder; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • tocilizumab augmentation (tocilizumab)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Major Depressive Disorder | Phase 2 | Status: TERMINATED | Results posted: 2020-10-20